Bone Health
End-to-End Support of Studies involving DXA: Obesity, Osteoporosis, Oncology, Infection disease, Nutrition and Metabolism Studies
Imaging for Safety, Efficacy, and Accelerated Approvals
Image Analysis Group (IAG) specializes in building imaging-powered differentiation strategies for novel drug candidates and biosimilars, with a strong focus on safety and efficacy trials in bone health, obesity, osteoporosis, sarcopenia, and related areas.
IAG’s team experience with using DXA, MRI, Fibroscan and X-ray in clinical trials spans over 20 years, with the company supporting large registrational studies and early phase projects. Leading proficiency with DXA imaging allows for precise measurement of lean mass, fat mass, and bone density changes, which are crucial metrics in evaluating the efficacy of obesity drugs.
Discover how you can drive significant cost savings (up to 35% trial budget reduction) and improve your chances of success through advanced patient stratification strategies that reduce trial length and cost.
+1200 patients
+50 Sites in all Europe
0.4 day from the upload to the QC report
2.2 days from QC report to Final Report
DYNAMIKA hosted all the DXA and X-ray images and analysis
Example 1
Centralized & Secure Data Collection
DYNAMIKA unifies global imaging into a secure, cloud-native platform. Fully compliant with 21 CFR Part 11 and ISO 13485 for regulatory readiness.
Real-Time Visibility & Oversight
Instant 24/7 access to imaging data for all stakeholders. Track site and reader performance to drive timely, informed decisions.
Quality Control & Automated Anonymization
Automated checks ensure high-quality, anonymized imaging datasets.Reduce errors, protect patient privacy, and safeguard trial integrity.
Seamless Data Integration & AI-Ready Infrastructure
Integrates easily with AI tools and analytics modules. Supports advanced endpoints and innovative trial methodologies.
Reduced Site Burden & Faster Trial Timelines
Simplified workflows lighten site workload and speed reviews. Fewer delays mean shorter trials and faster drug development.
Example 2
Consistent, Standardized Image Analysis
Centralized, protocol-driven reviews with automated checks. Delivers reproducible results and consistent clinical endpoints across sites.
Real-Time Collaboration & Audit Trails
All data and reviewer actions are logged centrally. Enables secure collaboration, transparency, and timely decisions.
Expert Review Efficiency & Reader Management
Simplifies reader assignment, monitoring, and workflow optimization.Reduces variability and flags outliers early in the process.
Integrated Advanced Analytics & AI Tools
Seamlessly connects with advanced analytics and AI modules.Gives reviewers faster access to biomarkers and novel endpoints.
Regulatory Compliance & Submission Readiness
Validated environment supporting 21 CFR Part 11 and ISO 13485. Ensures audit-ready data and smoother regulatory submissions.
Example 3
Consistent, Standardized Image Analysis
Centralized, protocol-driven reviews with automated checks. Delivers reproducible results and consistent clinical endpoints across sites.
Real-Time Collaboration & Audit Trails
All data and reviewer actions are logged centrally. Enables secure collaboration, transparency, and timely decisions.
Expert Review Efficiency & Reader Management
Simplifies reader assignment, monitoring, and workflow optimization.Reduces variability and flags outliers early in the process.
Integrated Advanced Analytics & AI Tools
Seamlessly connects with advanced analytics and AI modules.Gives reviewers faster access to biomarkers and novel endpoints.
Regulatory Compliance & Submission Readiness
Validated environment supporting 21 CFR Part 11 and ISO 13485. Ensures audit-ready data and smoother regulatory submissions.
Case Study:
One specific study, involving DXA analysis makes a vivid example. In 2021, IAG was contacted by a biotech company to support their Phase III trial. The objective was to utilize X-ray and DXA scans for combined eligibility as one of the criteria for the inclusion / exclusion of patients in their protocol. The Sponsor was looking for experts in the field, who can bring global network of sites, and execute screening with speed. IAG’s team partnered with the CRO and together we embarked on accelerating recruitment, opening out network of 750 obesity focused sites. The Study recruited faster than expected, saving Sponsor significant time and money. The data is currently being finalized to be submitted for regulatory review.
Given market dynamics, our latest focus has been on the safety and efficacy trials targeting bone health, obesity, OP, advanced oncology, sarcopenia, IO, spinal fusion.
Value of Partnering with IAG
Unparalleled Imaging Expertise
With over 20 years of experience in DXA, MRI, Fibroscan, and X-ray for clinical trials, IAG excels in both large registrational studies and early-phase projects.
Award-Winning Data Management Platform
IAG’s DYNAMIKA platform efficiently processes imaging data, supports all trial stakeholders, and delivers results via reports or dashboards, enabling rapid decision-making.
Time-Sensitive Solutions
Understanding the critical nature of time in clinical development, IAG provides transparent, efficient support to partners, readers, and sponsors throughout the trial process.
Global Support, Local Focus
We placed our team of imaging specialists in geographically important hubs (USA, EU, Asia, UK), which enables them to provide efficient answers to the sites and support global trials, with speed.
Value-Driven Partnerships
We prioritize delivering the highest quality data at competitive cost. We thrive to build long term relationships with our partners and clients.
Book a 30‑minute DXA endpoint strategy session
Planning a clinical trial involving DXA or other imaging modalities to assess safety and efficacy? Discover how IAG’s 20+ years of experience, global site network, and award-winning DYNAMIKA platform can streamline your imaging workflow and accelerate your trial outcomes.